Ginkgo Bioworks Holdings, Inc. (DNA)

Market Cap	468.90M
Revenue (ttm)	180.61M
Net Income (ttm)	-339.55M
Shares Out	56.84M
EPS (ttm)	-6.21
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	323,889
Open	8.25
Previous Close	8.40
Day's Range	8.24 - 8.65
52-Week Range	5.00 - 17.58
Beta	1.55
Analysts	Strong Sell
Price Target	9.00 (+9.09%)
Earnings Date	Nov 6, 2025

About DNA

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell programming in the United States. It operates through Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics and antibody developability Datapoints services, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 834
• Stock Exchange: NYSE
• Ticker Symbol: DNA
• Website: https://www.ginkgo.bio

Financial Performance

In 2024, Ginkgo Bioworks Holdings's revenue was $227.04 million, a decrease of -9.71% compared to the previous year's $251.46 million. Losses were -$547.03 million, -38.73% less than in 2023.

Analyst Summary

According to one analyst, the rating for DNA stock is "Strong Sell" and the 12-month stock price target is $9.0.

Price Target

$9.0

(9.09% upside)

Analyst Consensus: Strong Sell